Euglycemic Diabetic Ketoacidosis in a Patient with Type 2 Diabetes after Treatment with Empagliflozin

Diabetes Care

Volumn 39, Issue 1, 2016, Pages e3-

  Roach, Paris ^a   Skierczynski, Paul ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; INSULIN; LIRAGLUTIDE;

ADULT; ALCOHOL CONSUMPTION; ARTHRALGIA; CASE REPORT; CONFUSION; DIABETIC KETOACIDOSIS; DISEASE DURATION; DRUG SAFETY; DYSPNEA; FEMALE; HUMAN; LETTER; MIDDLE AGED; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT DURATION; TREATMENT WITHDRAWAL; VOMITING; WEAKNESS;

EID: 84962050697     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-1797     Document Type: Letter

References (2)

1. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015;38:1687-1693
2. Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 2015;38:1680-1686